Evidence map›Paper›PMID 35635082›Full record

ArticleBioengineered2022

Amentoflavone promotes ferroptosis by regulating reactive oxygen species (ROS) /5'AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) to inhibit the malignant progression of endometrial carcinoma cells.

Qi Sun, Peng Zhen, Dandan Li, Xiaochen Liu, Xinling Ding, Huihui Liu

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Chemopreventive mechanisms of amentoflavone: recent trends and advancements.Naunyn-Schmiedeberg's archives of pharmacology · 2023
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Qi SunTraditional Chinese Medicine (Mongolian Medicine) College, Chifeng University, Chifeng, Inner Mongolia, China.
Peng ZhenDepartment of Radiation Oncology, Chifeng Cancer Hospital, Chifeng, Inner Mongolia, China.
Dandan LiRehabilitation Department, Chifeng Cancer Hospital, Chifeng, Inner Mongolia, China.
Xiaochen LiuRehabilitation Department, Chifeng Cancer Hospital, Chifeng, Inner Mongolia, China.
Xinling DingDepartment of Human Anatomy, Basic Medical College, Chifeng University, Chifeng, Inner Mongolia, China.
Huihui LiuCancer Rehabilitation Department, Chifeng Cancer Hospital, Chifeng, Inner Mongolia, China.
Chifeng Municipal Hospital · CNChifeng University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It was reported that amentoflavone (AF) had anti-tumor ability. Therefore, this study aimed to investigate the role of AF in endometrial cancer as well as to discuss its underlying mechanism. The viability, proliferation, and apoptosis of endometrial carcinoma cells (KLE) with AF administration were detected by methyl tetrazolium (MTT) assay, clone formation, and terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) assays. Thiobarbituric acid reactive substance (TBARS) production and Fe

Indexed as

Endometrial NeoplasmsFerroptosisAMP-Activated Protein KinasesBiflavonoidsFemaleHumansReactive Oxygen SpeciesThiobarbituric Acid Reactive SubstancesTOR Serine-Threonine KinasesamentoflavoneAMP-Activated Protein KinasesBiflavonoidsMTOR protein, humanReactive Oxygen SpeciesThiobarbituric Acid Reactive SubstancesTOR Serine-Threonine KinasesAmentoflavoneendometrial cancer cellsferroptosisROS/AMPK/mTOR

Identifiers

PMID35635082
PMCPMC9275900
OpenAlexW4282034641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.